Major Depressive Disorder
Zuranolone effective in major depression
People with major depressive disorder experienced a significantly greater improvement in symptoms on zuranolone compared with placebo after 2 weeks of treatment, according to findings published in The American Journal of Psychiatry.
Phase 2 data support lysergide for major depressive disorder
A phase 2 trial provided positive results for the use of lysergide, otherwise known as LSD, in major depressive disorder, according to a press release.
First participants dosed in phase 1 study of nasal spray for treatment of MDD
A biopharmaceutical company announced the first participants have been dosed in its phase 1 clinical trial of PH10, an investigational pherine nasal spray to treat major depressive disorder.
FDA gives tentative approval for extended-release capsules of MDD treatment
The FDA has granted tentative approval to Zydus Pharmaceuticals Inc. to market extended-release capsules of levomilnacipran, a treatment for major depressive disorder, the company announced in a press release.
Intervention key for major depressive disorder to prevent treatment-resistant depression
For those with major depressive disorder, early intervention is crucial to address treatment-resistant depression, which may lead to higher disease burden on the patient and health care system, per a study published in JAMA Psychiatry.
Vistagen to acquire Pherin Pharmaceuticals, bolstering plans for therapeutic development
Vistagen receives FDA fast track for nasal spray for major depressive disorder
The FDA has granted Vistagen fast track designation for PH10, a nasal spray for the treatment of major depressive disorder, according to a company press release.
VIDEO: Cariprazine effective adjunctive therapy in MDD
In this video, Michael E. Thase, MD, MS, spoke with Healio about his poster presentation from the 2022 NEI Congress regarding clinical trial results on cariprazine for adjunctive treatment of major depressive disorder.
Deep learning may help predict mental disorder diagnosis
A multidiagnostic prediction model developed using deep learning was highly predictive of mental disorder diagnosis, according to new data published in JAMA Psychiatry.
Sage, Biogen submit NDA for depression treatment
Pharmaceutical company Sage Therapeutics and biotech firm Biogen announced completion of a rolling submission of a new drug application to the FDA for zuranolone for the treatment of major depressive disorder and postpartum depression.